The iBind™ Western System is an automated western blot processing platform that requires less primary antibody and enables sensitive, reproducible western results. All blocking, antibody incubation, and washing steps are hands-free, allowing you to load your solutions and walk away. There is no electricity or battery required. You can also use your existing chemiluminescent, chromogenic, or fluorescent western detection protocols, including HRP-, AP-, Alexa Fluor® dye–, and IRDye® (LI-COR®)–conjugated secondary antibodies.
- Cost savings—use up to 80% less primary antibody*
- Superior sensitivity—detect proteins at lower levels than manually processed blots
- Reproducibility—automated processing enables improved blot-to-blot consistency
One of the key elements of a successful western blot is the primary antibody; however, this reagent also contributes to over 90% of the total cost of the blot. Because the iBind™ Western System is more sensitive than manual processing methods, you can use less antibody and achieve similar results.
*Results may vary. The protocol for primary antibody use is 80% less than a traditional manual method.
Figure 1. Using chemiluminescent or fluorescence-based detection methods, you can use up to 80% less primary antibody than manual methods, saving you significant cost per blot.A 2-fold dilution series of EGF receptor control cell extract (30 µg, 15 µg, 7.5 µg, 3.75 µg, and 1.875 µg). Proteins were separated using the Mini Gel Tank Electrophoresis System and transferred to PVDF membranes using the iBlot® 7-Minute Blotting System. The blots were probed with a phospho-EGF receptor (Tyr1068) (1H12) mouse monoclonal antibody (1:1,000 dilution, equated to 2 µL antibody for the iBind™ device method and 10 µL antibody for the manual method) followed by a goat anti-mouse IgG (H+L) peroxidase conjugated antibody (1:360 for iBind™ device processing (5.55 µL); 1:1,800 for manual method (5.55 µL)). The standard iBind™ solution kit was used for the chemiluminescence blot (panel C, manual processing and panel D, iBind™ system processing); the fluorescence detection (panel A, manual processing and panel B, iBind™ processing) kit was used for fluorescence detection. These results demonstrate that western blots processed on the iBind™ device show comparable results to those obtained when western blots are processed manually, with lower overall primary antibody requirements for the iBind™ device.